Low Dose Naltrexone in Dermatology
Low Dose Naltrexone in Dermatology
J Drugs Dermatol. 2019 Mar 01;18(3):235-238
Authors: Jaros J, Lio P
Abstract
Low-dose naltrexone (LDN) has been successfully studied as an immunomodulatory and anti-inflammatory therapy in a wide range of conditions including Crohn’s disease, fibromyalgia, major depressive disorder, cancer, chronic regional pain syndrome, Charcot-Marie-Tooth, and multiple sclerosis.1-5 Recently, off label LDN has been shown to improve dermatologic conditions such as systemic sclerosis, Hailey-Hailey Disease, lichen planopilaris, and guttate psoriasis.6-9 In this article, we examine the existing evidence for use of LDN in skin disease and discuss its potential application in the treatment of atopic dermatitis (AD).
J Drugs Dermatol. 2019;18(3):235-238.
PMID: 30909326 [PubMed - as supplied by publisher]
Source: Journal of Drugs in Dermatology - Category: Dermatology Tags: J Drugs Dermatol Source Type: research
More News: Cancer | Cancer & Oncology | Charcot-Marie-Tooth Disease | Chronic Pain | Depression | Dermatitis | Dermatology | Fibromyalgia | Multiple Sclerosis | Pain | Psoriasis | Scleroderma | Skin